VERITAS: Harnessing the power of nomenclature in biologic discovery
ABSTRACTWe are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in co...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Book |
| Published: |
Taylor & Francis Group,
2023-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_a742f5fea5fa4f1dba7e11771a364ca2 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Riti Biswas |e author |
| 700 | 1 | 0 | |a Ed Belouski |e author |
| 700 | 1 | 0 | |a Kevin Graham |e author |
| 700 | 1 | 0 | |a Michelle Hortter |e author |
| 700 | 1 | 0 | |a Marissa Mock |e author |
| 700 | 1 | 0 | |a Christine E. Tinberg |e author |
| 700 | 1 | 0 | |a Alan J. Russell |e author |
| 245 | 0 | 0 | |a VERITAS: Harnessing the power of nomenclature in biologic discovery |
| 260 | |b Taylor & Francis Group, |c 2023-12-01T00:00:00Z. | ||
| 500 | |a 10.1080/19420862.2023.2207232 | ||
| 500 | |a 1942-0870 | ||
| 500 | |a 1942-0862 | ||
| 520 | |a ABSTRACTWe are entering an era in which therapeutic proteins are assembled using building block-like strategies, with no standardized schema to discuss these formats. Existing nomenclatures, like AbML, sacrifice human readability for precision. Therefore, considering even a dozen such formats, in combination with hundreds of possible targets, can create confusion and increase the complexity of drug discovery. To address this challenge, we introduce Verified Taxonomy for Antibodies (VERITAS). This classification and nomenclature scheme is extensible to multispecific therapeutic formats and beyond. VERITAS names are easy to understand while drawing direct connections to the structure of a given format, with or without specific target information, making these names useful to adopt in scientific discourse and as inputs to machine learning algorithms for drug development. | ||
| 546 | |a EN | ||
| 690 | |a Antibody engineering | ||
| 690 | |a antibody formats | ||
| 690 | |a antibody nomenclature | ||
| 690 | |a bispecific antibodies | ||
| 690 | |a multispecific antibodies | ||
| 690 | |a therapeutic antibodies | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 690 | |a Immunologic diseases. Allergy | ||
| 690 | |a RC581-607 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n mAbs, Vol 15, Iss 1 (2023) | |
| 787 | 0 | |n https://www.tandfonline.com/doi/10.1080/19420862.2023.2207232 | |
| 787 | 0 | |n https://doaj.org/toc/1942-0862 | |
| 787 | 0 | |n https://doaj.org/toc/1942-0870 | |
| 856 | 4 | 1 | |u https://doaj.org/article/a742f5fea5fa4f1dba7e11771a364ca2 |z Connect to this object online. |